Research location
Lille
Nord, France
Advertisement
Research activity in Lille
Nord, FranceCureCurrent currently publishes aggregate city-level research activity for this location: 90 trials and 93 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lille
89 linked trials · page 1 of 2A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation
RECRUITING
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07179380 · 2026-01-07 · 1 site observation
RECRUITING
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesNCT07115745 · 2025-09-04 · 1 site observation
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)NCT06863272 · 2025-07-03 · 1 site observation
RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06 · 1 site observation
RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25 · 1 site observation
RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationNCT05552157 · 2024-11-22 · 1 site observation
RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationNCT06647498 · 2024-11-22 · 1 site observation
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation
RECRUITING
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation
RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20 · 1 site observation
RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07 · 1 site observation
RECRUITING
Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of MotivationNCT05866575 · 2023-09-12 · 1 site observation
RECRUITING
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic ShockNCT04020263 · 2023-07-03 · 1 site observation
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · 2023-05-31 · 1 site observation
RECRUITING
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)NCT05489705 · 2022-08-16 · 1 site observation
RECRUITING
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for CancerNCT05460780 · 2022-07-01 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesNCT04300556 · 2020-08-06 · 1 site observation
RECRUITING
A Biological Atlas of Severe Obesity (Biological Tissue Collection)NCT01129297 · 2006-06-13 · 1 site observation
RECRUITING
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsNCT06553027 · 2024-09-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)NCT06305767 · 2024-03-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)NCT06220201 · 2024-03-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273 · 2024-03-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · 2024-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.NCT06024213 · 2023-06-06 · 1 site observation
COMPLETED
A Chart Review Study of Adults With Advanced NSCLCNCT05207423 · 2022-10-03 · 1 site observation
COMPLETED
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeNCT05399888 · 2022-08-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27 · 1 site observation
COMPLETED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · 2022-06-02 · 1 site observation
TERMINATED
Food Supplement Effect on Overweight or Moderate ObesityNCT05178667 · 2022-01-06 · 1 site observation
COMPLETED
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)NCT04945460 · 2021-12-29 · 1 site observation
COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)NCT05269394 · 2021-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)NCT04896008 · 2021-12-01 · 1 site observation
COMPLETED
A Study of Surgical Interventions in Fistulizing ConditionsNCT04940611 · 2021-08-05 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation
TERMINATED
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).NCT04895722 · 2021-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple SclerosisNCT04777539 · 2021-06-14 · 1 site observation
COMPLETED
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerNCT04752332 · 2021-05-10 · 1 site observation
TERMINATED
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)NCT04700124 · 2021-04-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)NCT04576988 · 2021-01-25 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 · 2021-01-22 · 1 site observation
COMPLETED
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)NCT04220866 · 2020-03-04 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068 · 2020-03-02 · 1 site observation
TERMINATED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNCT04129502 · 2020-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877 · 2019-10-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)NCT03867084 · 2019-05-28 · 1 site observation
COMPLETED
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT03778931 · 2019-05-10 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)NCT03820986 · 2019-03-12 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.